Print Page     Close Window     

SEC Filings

8-K
BEIGENE, LTD. filed this Form 8-K on 11/13/2017
Entire Document
 

Picture 3


 

advanced or metastatic esophageal, gastric, or gastroesophageal junction carcinoma.

BGB-290an investigational small molecule PARP inhibitor

·

Presented updated data from the global Phase 1 trial of BGB-290 in patients with advanced solid tumors at the ESMO 2017 Congress;

·

Initiated the following trials:

o

Global Phase 1 trial of BGB-290 in combination with temozolomide in locally advanced or metastatic solid tumors; and

o

Global Phase 1b/2 trial of BGB-290 in combination with radiation therapy and/or temozolomide in glioblastoma.

Corporate Development:

·

Closed our global strategic collaboration with Celgene Corporation. 

Expected Upcoming Milestones

BGB-3111 (BTK Inhibitor)

·

Present additional Phase 1 data for BGB-3111 in non-Hodgkin’s lymphoma, updated Phase 1 data for the combination of BGB-3111 and Gazyva®  (obinutuzumab), and initial Phase 1 data for the combination of BGB-3111 and BGB-A317 at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, GA, December 9-12, 2017.

BGB-A317 (PD-1 Antibody)

·

Present initial Phase 1 data for the combination of BGB-3111 and BGB-A317 at the 59th ASH Annual Meeting in Atlanta, GA,  December 9-12, 2017; and

·

Initiate Phase 3 trials of BGB-A317 in China in the fourth quarter of 2017 or the first quarter of 2018.

 


 


© 2016 BeiGene. All Rights Reserved.